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The use of nanocarriers for intracellular transport of actives has been extensively studied in 
recent years and represents a central area of Nanomedicine. The main novelty of this paper 
lies on the use of nanogels formed by a low molecular weight gelator (1). Here, non-
polymeric, molecular nanogels are successfully used for intracellular transport of two 
photodynamic therapy (PDT) agents, Rose Bengal (RB) and Hypericin (HYP). 
The two photosensitizers (PSs) exhibit different drawbacks for their use in clinical 
applications. HYP is poorly water-soluble, while the cellular uptake of RB is hindered due 
to its dianionic character at physiological pH values. Additionally, both PSs tend to aggregate 
precluding an effective PDT. Despite the different nature of these PSs, nanogels from gelator 
1 provide, in both cases, an efficient intracellular transport into human colon adenocarcinoma 
cells (HT-29) and a notably improved PDT efficiency, as assessed by confocal laser scanning 
microscopy and flow cytometry. Furthermore, no significant dark toxicity of the nanogels is 
observed, supporting the biocompatibility of the delivery system. The developed nanogels 
are highly reproducible due to their non-polymeric nature and their synthesis is easily scaled 
up. The results here presented confirm thus the potential of molecular nanogels as valuable 
nanocarriers, capable of entrapping both hydrophobic and hydrophilic actives, for PDT of 
cancer. 
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Nanomedicine, which uses biocompatible nanoparticles for diagnosis, delivery or sensing 
purposes,1 has received extensive interest in recent years as demonstrated by the increasing 
number of publications engaging with this topic. For example, more than 100 review papers 
were published in 2019 containing the term "Nanomedicine" in the title. Nanomedicine 
constitutes a vast area of research due to the wide variety of nanoparticles that can be 
employed and the many therapeutic targets that can be introduced. A common approach in 
Nanomedicine is to use nanocarriers for the intracellular delivery of molecular or 
macromolecular bioactive species. Examples include liposomes, solid-lipid nanoparticles, 
polymeric micelles and nanogels, polymer-drug conjugates, albumin and silica nanoparticles. 
Despite the large number of potential nanomedicines reported in the literature, only a few 
tens of them have been approved by the FDA for clinical use due to the many pitfalls found 
in the translation from bench to clinical practice.2 
Conventional polymeric nanogels (nanohydrogels), nanoparticles formed by polymeric 
networks that retain large quantities of water, have received extensive interest in recent years 
due to their potential for biomedical applications.3 Following the initial work from 
Vinogradov, the vast majority of nanogels consist of covalently crosslinked networks.4 
Alternatively, examples of physically crosslinked nanogels have also been reported in the 
literature and include those formed by the self-assembly of amphiphilic block copolymers,5 
hydrophobized polysaccharides6 or DNA.7 
Lately, our group has been interested in the study of molecular nanogels, namely nanogels, 
formed by aggregation of small molecules instead of polymers.8,9 The use of molecular 
nanogels aims to solve some critical drawbacks of polymeric nanogels in their use as 
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biomedical carriers,10 such as biodegradability, stimuli responsiveness, polymer 
polydispersity, and batch-to-batch reproducibility. Interestingly, nanogels constituted by low 
molecular weight species have an apparent relationship to their macroscopic counterparts, 
supramolecular (molecular) gels, which are soft materials formed by self-assembled fibrillar 
networks widely studied in recent decades.11  
Nanocarriers are used for therapeutic applications being cancer the central area of interest.12 
In relation to this paper, photodynamic therapy (PDT) has been clinically used for the 
treatment of solid tumors for the past 25 years.13 PDT treatment involves a systemically or 
topically administered photosensitizer (PS) followed by site-specific irradiation of the PS 
with the appropriate wavelength to generate reactive oxygen species (ROS).14 Site-specific 
irradiation causes cancerous cells to perish while sparing healthy tissues and organs, so PDT 
avoids the frequent systemic severe toxicity and adverse effects of other treatments. The 
mechanism to generate ROS consists of light absorption by the PS to yield the first excited 
state, 1PS*, and then, after intersystem crossing, the excited triplet state, 3PS*. The latter is 
quenched by oxygen present in the medium (3O2) generating singlet oxygen (
1O2), via type 
II mechanism (energy transfer), and other cytotoxic species such as radical anion superoxide 
(O2
.-), hydroxyl radical (·OH) or hydrogen peroxide (H2O2), via type I mechanism (electron 
transfer).15 The use of nanoparticles or nanocomposites for PDT has received increasing 
attention in recent years.16 In this paper, we specifically address the application of molecular 




Scheme 1. Chemical structure of hydrogelator 1, Rose Bengal and Hypericin. 
Rose Bengal (RB, Scheme 1) is a water-soluble, well-studied synthetic dye that absorbs 
strongly around 550 nm. It sensitizes the formation of 1O2 with a high quantum yield (Φ(
1O2) 
= 0.75 under 540 nm light irradiation), being a potent photosensitizer for type II PDT.17 RB 
is versatile and applicable to a wide range of fields, from photocatalysis18 to biomedicine. In 
this latter context, RB has had a profound impact as a therapeutic agent, with promising 
results in preclinical studies as PS for PDT treatment of cancer and the prevention of 
infectious diseases spreading.19 Besides, its long history of safe use in systemic diagnosis of 
hepatic function, as well as in ophthalmology, has facilitated RB to advance into different 
clinical trials. An essential drawback in the therapeutic use of RB is that, at physiological 
pH, the predominant species is a dianion, which is inhibited from crossing cell membranes 
and suffers from poor intracellular uptake ability.20 The incorporation of the dye into 
nanocarriers has proved to overcome this limitation and, also, does not interfere in the 
photodynamic efficiency of RB.21 For example, a favored intracellular accumulation, and an 
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enhanced phototoxic effect were achieved for RB loaded into silica nanoparticles (oral and 
breast cancer cells),22 cationic dendrimers (basal carcinoma cells),23 and covalently bond to 
gold nanoparticles (oral cancer cells).24 Higher phototoxicity was also reported for RB 
incorporated into silica nanoparticles (skin cancer cells),25 chitosan microcapsules (breast 
cancer),26 zinc oxide nanoparticles (cervical cancer cells),27 albumin (lung cancer cells)28 and 
PAMAM dendrimers (Dalton's lymphoma ascites cells).29 
The other PS studied here, Hypericin (HYP, Scheme 1), is a polyphenolic molecule obtained 
from the plant St John's Wort (Hypericum perforatum) with a broad pharmacological 
spectrum. It has an absorption maximum at ca. 590 nm and is also an efficient 
photosensitizer.30 Upon light activation, both type I and type II mechanisms have been 
proposed to explain its PDT activity.31 Additional processes have been suggested as 
contributors of its phototoxicity, as the formation of hypericin radicals or a hypericin-induced 
pH drop.32 Some advantages of the photosensitizing activity of HYP are its minimal or no 
dark toxicity33 and its preferential accumulation in neoplastic tissues.34 The HYP-PDT 
antineoplastic efficacy for cancer treatment has been demonstrated in several in vitro and in 
vivo studies,30 and three clinical trials for various skin disorders.35 The light-dependent 
fungicidal, bactericidal and antiviral effects of HYP have also been reported.36 A critical 
drawback in the clinical application of HYP in PDT comes from its low water solubility.37 
Furthermore, HYP tends to form non-fluorescent aggregates in aqueous media, which show 
a suppressed photodynamic activity and, therefore, low phototoxicity on cells.38 Several HYP 
nanocarriers have been investigated aiming to overcome these limitations. For example, 
encapsulated HYP in polylactic acid nanoparticles or copolymer micelles39 showed improved 
intracellular accumulation in ovarian tumor animal models; solid-lipid nanoparticles were 
7 
 
useful as HYP transporters into cervical adenocarcinoma cells;40 and HYP encapsulated into 
block copolymers41 and calcium phosphate nanoparticles42 improved the in vitro 
antimicrobial and antileishmanial PDT, respectively. Additional recent examples include 
HYP loaded in proteins graphene oxide and composite nanoparticles.43  
It has been stated that the use of nanocarriers is the defining characteristic of the so-called 
third generation of PSs.44 Ideally, these nanosystems should incorporate the PS without loss 
or alteration of the sensitizer activity.45 Here, we address the use of a novel nanocarrier, 
molecular nanogels, for the improvement of cellular uptake of RB and HYP and, thus, 
improvement of their PDT effect. As abovementioned, these molecules present opposite 
physicochemical nature, high polarity and water solubility for RB, and low polarity and poor 
aqueous solubility for HYP, which, in both cases, leads to drawbacks for their use in clinical 
PDT. Results presented here highlight the versatility of the molecular nanogels used as 
carriers, which enhance cellular uptake of the sensitizers favoring their activity as PDT 
agents. 
RESULTS AND DISCUSSION 
The preparation of the molecular nanogels from gelator 1 ((S)-4-((3-methyl-1-(nonylamino)-
1-oxobutan-2-yl)amino)-4-oxobutanoic acid, see Scheme 1) was previously reported in detail 
by our group. These particles have a gel-like nature as they are constituted mainly by water, 
according to static light scattering measurements.9 Scheme 2 outlines the preparation of 
photosensitizer-loaded nanogels (PS@1) carried out in this work. In the first step, a gel of 1 
in toluene is formed in the presence of the corresponding PS. Solvent removal under vacuum 
gave a xerogel film that was suspended, with sonication, in PBS (pH 7) to afford a colloid 




Scheme 2. Pictorial representation of the process followed to prepare PS@1 nanogels. 
Rose Bengal loaded nanogels. 
Although RB is insoluble in toluene due to its ionic character, the gelator facilitated its 
dispersion in toluene. A related behavior has recently been reported by us for the same system 
in dichloromethane.46 Therefore, homogenous gels in toluene containing RB could be 
prepared by cooling down to room temperature a hot solution containing 1 (7.3 mM) and RB 
(40 µM). Following the procedure described above (xerogel formation and sonication), a 
colloid containing RB-loaded nanogels, RB@1 was obtained. The same protocol used to 
obtain RB@1 was repeated without 1, investigating how the different steps could affect the 
RB. It was confirmed that the photosensitizer remained stable throughout the procedure.  
The analysis of the RB@1 samples by UV-Vis spectroscopy (Figure 1) showed that the 
maximum absorption red-shifted from 549 nm for free RB to ca. 560-570 nm for the RB@1 
species in PBS. This red-shift indicates RB being in a less polar environment in the nanogel 
than the one found in a conventional water solution. The strong solute-solvent interactions 
of RB with water, which stabilize the ground state of the PS, would be perturbed in the more 
hydrophobic environment of the nanogel. This type of effect diminishes the energy gap 
between the frontier orbitals, leading to λmax red-shifts in the absorption spectrum. Similar 
Hot solution of
1 + PS in toluene












bathochromic shifts have been reported due to the incorporation of RB in hydrophobic 
environments.47 It has to be noted that the mentioned shift indicates that a significant amount 
of  RB is loaded in the nanogel particles, but the presence of free RB in the system can not 
be discarded. A 10 nm bathochromic shift was also observed for the maximum of the 
fluorescence emission spectra of the RB@1 samples (from ca. 570 nm to ca. 580 nm). 




































Figure 1. Normalized UV-Vis absorbance (dashed line) and fluorescence emission (solid 




RB tends to aggregate in dimers and higher multimers, a phenomenon that is detrimental for 
its use in PDT as ROS yields are reduced; and this aggregation can be estimated from the 
intensity ratio of the shoulder to the maximum peak in the absorption spectrum. The intensity 
ratio for RB@1 is almost identical to the ratio of a free RB standard solution in PBS, in which 
RB is in monomeric form. 
The amount of RB in these samples was determined by UV-Vis spectroscopy. The absorption 
at the maximum intensity wavelength was used to calculate the concentration of RB, based 
on a linear calibration constructed for free RB in PBS. It has to be noted that nanogel particles 
originate considerable light dispersion, resulting in a notable increase of the absorption 
baseline of the spectrum. For this reason, the quantification of RB was performed from 
baseline-corrected spectra (see Figures S1-S2.). The results obtained in this way were 
coincident with those achieved by nanogel disassembly by the addition of DMSO. The 
concentration of RB in RB@1 nanogel samples was found to present some variation in the 
different batches with an average value of 6 ± 3 µM, which represents a drug loading of 0.8 
%w/w (the concentration of 1 in the samples was determined to be 0.7 mg/mL9). For control 
purposes, in the following experiments, RB solutions in PBS with the same concentration 
present in RB@1 samples were used. 
RB@1 nanoparticles were characterized by dynamic light scattering (DLS) and transmission 
electron microscopy (TEM) (see Figure 2). DLS revealed a number averaged diameter (Dn) 
of 218 nm (std dev = 6, polydispersity index = 0.24). Aging for 24 h or 1:3 dilution in the 
cell culture medium did not modify the size distribution significantly. Z-potential was 
determined to be -33.9 mV (std dev = 4.1, see Figure S15). This value indicates colloidal 
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stability towards aggregation, and the negative value reflects the ionizable nature of the 
carboxylic acids, which should be in part as carboxylates in the nanogel. 
Regarding TEM, spherical and spherulitic objects were observed, which, as proposed 
previously,9 would indicate that the nanogels would correspond to nucleation points that, in 
more concentrated solutions, would yield self-assembled fibrillar networks. The size of the 
particles observed by TEM is in good agreement with that obtained by DLS. 
 
Figure 2. Analysis of RB@1 particles. TEM images (left) and number averaged diameter 
distribution obtained by DLS (right).  
Samples were diluted 1:3 in medium and tested in human colon adenocarcinoma cells (HT-
29). This dilution was chosen because preliminary assays with 1, using the Trypan blue 
exclusion test, revealed that a 1:3 dilution of the nanoparticles with medium presented 
negligible cytotoxicity, slightly increased for a 1:2 dilution (see Figure S3). It has to be noted 
the medium refers to Dulbecco’s modified Eagle’s medium (DMEM) used without the 
addition of Phenol Red to avoid interferences in optical measurements and, in the cases 
indicated in the Methods section, without fetal bovine serum to promote starvation. 
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The incorporation of RB in the cells was studied using confocal laser scanning microscopy 
(CLSM) and flow cytometry after a 24 h incubation period with RB@1 nanogels. The solvent 
used to prepare the nanogels (PBS, pH 7) was used as the negative control. As shown in 
Figure 3, the confocal microscopy analysis (λex 514 nm) of cells incubated with RB@1 or 
free RB shows homogenous fluorescence intensity revealing a non-specific distribution of 
the PS within the cytoplasm. Previous reports indicate that RB accumulates in membranes of 
normal cells but it has been localized in lysosomes of melanoma cell lines.48,49 The apparent 
intensity of intracellular fluorescence measured by CLSM is notably higher for the cells 
treated with RB@1 nanogels than for those treated with RB alone. Flow cytometry analysis 
is entirely consistent with this observation. Three different nanogel batches were tested in 
duplicate, and the mean cell fluorescent intensity (λex 488 nm) over negative control for the 
RB@1 samples was found to be ca. 70 times higher than that for the free RB solutions. Such 
difference should not be ascribed to the interaction of RB with the nanocarrier, which 
increases only moderately RB fluorescence. 
 
Figure 3. Confocal laser scanning microscopy images of HT-29 cells incubated for 24 h with 
free RB and RB@1 nanogels (λex 514 nm). Negative control corresponds to cells incubated 
with PBS. [RB] = 1.1 M. Scale bar =16 m. 
RB@1RB Negative control 
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As previously mentioned, the low cellular uptake of free RB is ascribed to its anionic 
character, resulting in reduced cellular membrane permeation.20,50 The photosensitizer 
entrapped in nanogels of 1 would act as stealth RB. Some authors have metaphorically coined 
this strategy 'a Trojan horse approach'.51 Presumably, the enhanced cellular uptake is a 
consequence of differences in the mechanism of RB internalization. Endocytosis, a common 
mechanism described for internalization of nanosized particles, probably participates in the 
case of the nanometric gel particles.52 
The potential use of the RB@1 nanogels for PDT was also investigated. HT-29 cells were 
incubated for 24 hours with either RB@1 nanogels or free RB in PBS and subjected to 
irradiation with a white light source (two light-emitting diodes (LEDs) 11W power each one, 
em = 400-700 nm) for 2 minutes. A negative control experiment was performed with HT-29 
cells incubated with PBS and irradiated under the same conditions. The cell apoptosis and 
viability were studied 24 h after the irradiation. It has to be noted that once cells enter in 
contact with ROS, different mechanisms of cell death are triggered, being necrosis and 
apoptosis the best known. Apoptosis is a gene-directed cell suicide process undergone when 
cells become damaged or are no longer needed. Necrosis has been considered a passive form 
of cell death occurring as a consequence of physical or chemical attack to the cell. Necrosis 
and apoptosis are very distinct morphologically since the former is accompanied by cellular 
and organelle swelling, membrane breakdown, and content release to the extracellular space, 
while apoptosis involves cell shrinkage and blebbing of the plasma membrane.53 A third 
mechanism, autophagy, is a predominantly cytoprotective process that has been linked to 
both necrosis and apoptosis death, serving either as a pro-survival or pro-death function.54 
Finally, it must be recalled that the emerging paraptosis death mechanism is gaining 
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increasing attention within the PDT community,55 and could also play a role in explaining 
the activities of our systems. However, its study is out of the scope of this research. 
Elucidating which mechanism is operating in the cellular death provides useful information 
for the rationalization and improvement of PDT. 
In the study of RB@1 PDT activity, viability and apoptosis were evaluated by flow cytometry 
using a commercial kit that double-stains the cell population. Apoptosis was inferred by 
staining with FITC-Annexin V, which detects externalized phosphatidylserine, a feature of 
the early phases of apoptosis. Viability was detected with propidium iodide, which signals 
the loss of membrane integrity that accompanies the later stages of cell death. Three different 
batches of RB@1 nanogels were tested in duplicate, and the results are summarized in Figure 
4 (see dot plot at Figure S13). RB@1 internalization results in a dramatic enhancement of 
the measured PDT activity when compared to the cells treated with free RB and with PBS. 
These findings are in accordance with the higher efficiency of cellular uptake of RB@1 than 
that of free RB. RB@1 produces an apoptotic induction or more than 70% of the cell 
population. In comparison, the percentage of apoptotic cells for HT-29 cells incubated with 
free RB close to the basal level of 15% observed for PBS control. Only apoptosis was 
observed as a cell death mechanism, both in staining and scattering analysis of flow 
cytometry data. This result is in agreement with a previous report that also finds apoptosis to 
be the preferred mechanism of cell death using RB.56 Regarding dark toxicity, no significant 
increase in cell death was observed when the cells were incubated under the same conditions 
as those indicated in Figure 4 but were not subject to irradiation (Figure S4) thus, confirming 
the biocompatibility of the RB@1. The phototoxicity of unloaded nanogels was also 
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investigated using flow cytometry, and no cell death was observed when HT-29 cells were 














Figure 4. Results obtained by flow cytometry of cell viability and early apoptosis in PDT 
experiments (2 min irradiation) with HT-29 cells and RB as a photosensitizer. Annexin V-
FITC/propidium iodide was used for staining. Negative control corresponds to cells 
incubated with PBS. The results are the average of three different batches analyzed in 
duplicate (average [RB] in culture media was 2 M).  
Comparison with precedent in vitro studies using other nanocarriers has only a relative value 
considering the different types of cells examined and experimental conditions. The use of 
RB-loaded cationic dendrimers resulted in an induction of apoptosis to 40-60% of different 
basal carcinoma cells.23 In another example, organically modified mesoporous silica 
nanoparticles loaded with RB reduced ca. 40% cell proliferation in a skin cell cancer culture 
compared to the control.25 
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As RB is a type II photosensitizer, the photogeneration of 1O2 in aqueous solutions of RB@1 
was spectroscopically measured using 9,10-anthracenediyl-bis(methylene)dimalonic acid 
(ABDA) as 1O2 chemical trap, which is a water-soluble probe for this ROS.
57 It was observed 
that the entrapment of RB in the nanogel reduces moderately the rate of 1O2 production, being 
the kinetic constants measured 8.8 and 22.5 mM-1·min-1for RB@1 and RB, respectively 
(Figure S6). A possible rationale for this behavior is that the nanogel environment lowers the 
diffusion rate of O2 inside the nanogel, and consequently, the diffusion of 
1O2 outside of the 
nanoparticle.58 Also, it has to be noted that the efficiency of 1O2 generation in cuvette, hence 
in the absence of cells, could not be reflecting the situation in the biological context since 
once the RB@1 system crosses the cellular membrane, the PS could be released due to the 
disassembly of the nanoparticle.  
Hypericin loaded nanogels 
Hypericin-loaded nanogels (HYP@1) were obtained from a gel of 1 in toluene formed in the 
presence of HYP (25 M), which is soluble in hot toluene in the M range of concentrations 
used in this experiment. As described in Scheme 2, solvent removal affords a xerogel, which 
is sonicated in PBS to form a sample of HYP@1 nanogels. As shown in Figure 5, the 
absorption spectrum of HYP@1 exhibits two well-defined peaks in the range 525-625 nm, 
with the dominance of the red-most band. However, the absorption spectrum of HYP in PBS 
shows a broadening of visible bands and less vibronic structure (Figure S7). These data 
suggest that the monomeric form of HYP is present in the nanogels. In contrast, aggregates 
are formed in the absence of nanoparticles. Similar absorption spectra, ascribable to the 
monomeric form of HYP, have been previously reported for the incorporation of this 
molecule in membranes, nanoparticles or proteins.59 As for fluorescence, HYP@1 in PBS 
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shows a fluorescence emission spectrum with band maxima at 597 and 647 nm while HYP 
in PBS shows no fluorescence under the same conditions. These results also point to the 
presence of free HYP in the nanogels and aggregated, non-emissive, HYP in the aqueous 
medium. 



















































Figure 5. UV-Vis absorption and fluorescence emission (λex 550 nm) spectra of a 
representative HYP@1 sample (solid line) and HYP in PBS. 
A blue-shift going from HYP in DMSO to HYP@1 in PBS is detected both for absorption 
and emission maxima (Figure S7; 599 to 596 nm and 603 to 597 nm, respectively). This 
maxima displacement indicates that the environment of HYP in the nanogels presents 
reduced polarity compared to DMSO.60 Hypericin could be establishing π-π interactions with 
hydrophobic areas or hydrogen bonds with the gelator molecules, as has been suggested for 
other systems.61 
The quantification of HYP in the nanogel samples was performed by UV-Vis spectroscopy. 
The absorption at the maximum intensity wavelength was used to calculate the concentration 
of HYP, based on a linear calibration made from free HYP in DMSO. As in the case of 
RB@1, HYP@1 nanogel particles originate considerable light dispersion, and quantification 
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of HYP was performed from baseline-corrected spectra (see Figure S2). The results obtained 
in this way were coincident with those achieved by nanogel disassembly by the addition of 
DMSO. An average loading of 0.7 ± 0.3 µM of HYP (0.05 %w/w drug loading) was obtained. 
Similar loadings were reported for other HYP-encapsulated systems.41,62 Samples prepared 
as HYP@1 nanogels but without the addition of gelator were used as a control (HYP in PBS 
from here on). The maximum concentration of HYP that can be solubilized in PBS by this 
method was 0.09±0.05 µM, which is one order of magnitude lower than the solubility in the 
presence of the nanogels. 
 
Figure 6. Analysis of HYP@1 particles. TEM images (left) and number averaged diameter 
distribution obtained by DLS (right). 
HYP@1 nanoparticles were characterized by dynamic light scattering (DLS) and 
transmission electron microscopy (TEM) (see Figure 6). The results are similar to those 
obtained for RB@1 samples regarding both morphology and sample stability. DLS revealed 
a number averaged diameter (Dn) of 137 nm (std dev = 7, polydispersity index = 0.32). Aging 
for 24 h or 1:3 dilution in the cell culture medium did not modify the size distribution 
2 m
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significantly. Additionally, the Z-potential was similar to that measured for RB@1, with a 
value of -36.1 mV (std dev = 1.8, see Figure S16). 
The cellular uptake of HYP@1 by HT-29 cells was also studied using flow cytometry and 
confocal laser scanning microscopy similarly as described above for RB@1. HT-29 cells 
were incubated for 24 h with HYP@1 nanogels and the average fluorescence emission per 
cell measured by flow cytometry was used as an indicator of the internalization of HYP. Due 
to the very low solubility of HYP in PBS, control samples at the same concentration were 
prepared using 1% v/v DMSO as co-solvent (from here on, PBS-DMSO). However, PBS 
without any DMSO was used as the solvent for the samples with HYP@1. Flow cytometry 
analysis of three different nanogel batches was performed in duplicate. The mean cell 
fluorescent intensity (λex 488 nm) was found to be ca. three times higher for the HYP@1 
system than for the sample containing HYP in PBS-DMSO. Moreover, the internalization of 
HYP for cells incubated with HYP@1 in PBS gave a 14 times higher fluorescence intensity 
than that obtained for HYP dispersed in PBS without DMSO. Care should be taken to 
interpret the intracellular fluorescence intensity of HYP due to the sensitivity of its emission 
efficiency to aggregation and polarity. It is assumed that the nanogel is disassembled in the 
cell, and the HYP emission from the different samples can be compared. Confocal laser 
scanning microscopy images (Figure 7 and S8) agree qualitatively with the flow cytometry 
data, indicating significantly higher emission inside the cells treated with HYP@1 than inside 
cells treated with free HYP administered in PBS or in PBS-DMSO. The images reveal that 
HYP is preferentially accumulated in the membrane when cells are incubated with the HYP 
in PBS-DMSO sample (see Figure S5). However, when HYP@1 is studied, the HYP is 
localized in the cytoplasm in a non-specific manner. It has been reported that HYP, due to its 
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pronounced hydrophobic character, accumulates in lipid membranes.63 Noticeably, it was 
described that, for HeLa cells, the use of serum in the culture media with HYP led from a 
plasma membrane staining (with non-fluorescent aggregates in the rest of the cell) to a non-
specific, cytoplasmic localization.64 This could be the case for HYP@1 nanoparticles, and 
the nanogel would play a similar role to that of the serum proteins.  
 
Figure 7. Images from confocal laser scanning microscopy; λex 561 nm. Cells were incubated 
for 24 h with the samples. [HYP] = 0.2 M. Scale bar = 20 m. 
The efficiency of HYP@1 for in vitro PDT was also studied in HT-29 cells as described 
above for RB@1. For HYP@1, viability and apoptosis were detected based on changes in 
the permeability of cell membranes, using a commercial kit with YO-PRO®-1/propidium 
iodide staining. Three different batches of HYP@1 nanogels were tested in duplicate, and 
the results are summarized in Figure 8 (see dot plot at Figure S14). Irradiation of cells 
incubated with HYP@1 in PBS and HYP in PBS-DMSO caused in both cases a significant 
reduction in cell viability. For example, cell viability is ca.10 % for HYP@1 and 85 % for 
negative controls. On the other hand, no photoactivity was found for controls using HYP in 
PBS without DMSO, being the percentages of viable cells near the basal level (see Figure 
S9). Also, low dark toxicity was observed in all cases (see Figure S10). 
HYP (PBS) HYP@1HYP (PBS-DMSO)Negative control 
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Irradiation of the cells in the presence of HYP@1 shows, according to the alterations in the 
light scattering pattern of the cells observed by flow cytometry (Figure S14), a prevalence of 
necrosis over apoptosis. This effect had also been observed previously in HT-29 cells treated 
with HYP and exposed to an extensive range of PDT doses.65 Protocols favoring apoptosis 
are recommended when PDT is applied for curative treatment of in situ neoplasia. However, 
the induction of necrosis, accompanied by an inflammatory reaction, has been reported as a 
good option for curing infiltrative tumors.66 The PDT activity obtained here is comparable to 
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Figure 8. Results obtained by flow cytometry of cell viability and apoptosis in PDT 
experiments (2 min irradiation) with HT-29 cells and HYP as a photosensitizer. YO-PRO®-
1/propidium iodide was used for staining. Negative control corresponds to cells incubated 
with PBS. The results are the average of three different batches analyzed in duplicate. [HYP] 




A relevant advantage of HYP@1 over free HYP for their use in PDT is the avoidance of 
DMSO as a co-solvent. The use of solvents in cell cultures, commonly ethanol and DMSO, 
has some drawbacks that should not be neglected. For example, water-DMSO systems with 
0.25 and 0.5% of the organic solvent induce inhibitory effects in some cell types and 
stimulatory impact in others.67 Besides, the proportion of a co-solvent can change in 
biological media, causing HYP aggregation.  
Finally, the study of photogeneration of 1O2 in aqueous solutions of HYP@1 by ABDA 
revealed that the photoactivity is similar to that of aggregated, poorly fluorescent, HYP in 
PBS control samples (kinetic constants of 1.9·10-4 and 1.1·10-4 s-1 respectively, see Figure 
S6). These results are in sharp contrast with the much more effective PDT observed in cells 
treated with HYP@1 compared to those treated with HYP in PBS. A rationale for this 
behavior could be that encapsulation of HYP in the nanogel blocks significantly its action as 
a PDT agent, being the system activated for PDT upon intracellular nanogel disassembly. A 
similar effect was observed for the encapsulation of HYP in solid-lipid and polylactic acid-
based nanoparticles.40 Alternatively, it must be recalled that other ROS different from 1O2 
have been reported for HYP.31 Hence, a more in-depth study would be needed to disclose 
which mechanism (type I or II), namely, which ROS (1O2 or O2
.-), is responsible for the 
observed PDT effects. The cytotoxic ability of 1O2 has been linked to apoptotic changes, 
while the impact of O2
.- is more associated with lipid oxidation, altering membrane 
functions.68 The different cell death mechanism observed for each ROS would reinforce the 
idea that the necrotic effects of HYP here reported are more likely due to O2
.- at membranes 




The use of non-polymeric, molecular, nanogels as vehicles for intracellular transport of 
actives has been hardly studied to date. Here, the nanogels formed by compound 1, whose 
preparation and characterization were reported in a previous work,9 show the capability of 
entrapping and promoting intracellular transport of two PDT agents, RB and HYP. These 
photosensitizers present markedly different physicochemical characteristics. RB is a 
dianionic species at neutral pH and water-soluble, while HYP is rather hydrophobic. These 
two compounds can be considered paradigmatic examples of substances that need vehicles 
for intracellular transport. The cellular membrane hinders the intracellular transport of 
anionic species like RB. At the same time, hydrophobic compounds such as HYP present 
such low solubility in plain water that their concentration in solution is not enough to be 
effective in PDT. Seemingly, the molecular nanogels can entrap HYP in the hydrophobic 
domains of the hydrogel particle, formed by self-assembled molecules of 1. In contrast, in 
the case of RB, most likely adsorption through ion-dipole interactions with the polar units of 
the gel particle explains its incorporation. The mechanism of cellular uptake of the loaded 
nanogels is probably endocytosis considering the precedents in the literature but has not been 
studied in this work. Considering that hydrophobic interactions dominate the nanogel self-
assembly, it seems feasible that the particles would be disassembled in the cellular medium 
upon, for example, interaction with proteins.  
The results obtained by flow cytometry revealed an effective PDT action for both RB@1 and 
HYP@1 nanogels, showing no relevant dark toxicity confirming the biocompatibility of the 
delivery systems. The PDT efficiency compares well with previous reports using different 
nanocarriers. We believe that the use of nanogels described here presents an added value 
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coming from its molecular nature. Stimuli responsiveness of molecular particles would 
permit site-specific release/activation of the loaded species. Additionally, the molecular 
nature of the carrier should favor its biodispositon and avoid reproducibility and 
polydispersity issues associated with polymeric materials. 
Finally, it is worth noting that the versatility of the nanogels could potentially permit 
simultaneous loading of PS and upconversion nanoparticles, affording IR-promoted PDT, a 
possibility that may be studied in future work.69 
 
METHODS 
Materials and general methods 
Commercially available reagents and HPLC grade solvents were used as received and 
purchased from Sigma-Aldrich and Fisher Scientific unless otherwise stated. Phosphate 
buffered saline (PBS) tablets were used to prepare a PBS solution containing 0.01 M 
phosphate buffer, 0.0027 M potassium chloride, and 0.137 M sodium chloride. The pH was 
adjusted to 7.0, and the solution was filtered using a 0.22 µm pore nylon filter. Toluene was 
also filtered through a 0.45 µm pore nylon filter. MiliQ water was always used. Rose Bengal 
was used as the sodium dianionic form. Hypericin was obtained from HWL ANALYTIC 
GmbH. The solutions containing the photosensitizers were protected from light to avoid 
photobleaching.  
Sonication was carried out with Elmasonic S 60 H (Elma) or Fisherbrand FB15053 (Fisher 
Scientific) ultrasonic units. Centrifugation was performed in vials using a Hettich EBA 20 
centrifuge at room temperature or in Eppendorf tubes (1.5 mL) using a Beckman Coulter 
Allegra™ X-22R centrifuge at 15 oC.  
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UV-vis absorption spectra of the samples were recorded using a JASCO V-630 
spectrophotometer with an ETCS-761 Peltier unit for temperature control. Measurements 
were performed at 25 oC, and samples were loaded into 1.5 mL or 3 mL quartz SUPRASIL™ 
cuvettes, 10 mm optical path length, from Hellma Analytics. 
Fluorescence emission spectra were obtained using a JASCO FP-8300 spectrofluorometer 
equipped with an ETC-815 Peltier accessory. Measurements were performed at 25 oC, and 
samples were loaded into 3 mL optical glass cuvettes, 10 mm optical path length, Hellma 
Analytics. 
Size measurements of nanogels were performed by dynamic light scattering (DLS) using a 
Zetasizer Nano ZS (Malvern). Analyses were carried out using a He-Ne laser (633 nm) at a 
fixed scattering angle of 173o. Automatic optimization of beam focusing and attenuation was 
applied for each sample. Nanogel suspensions were measured in 3 mL disposable PMMA 
cuvettes (10 mm optical path length). The particle size was reported as the average of three 
measurements. Z-potential measurements were performed at 25 oC using Laser Doppler 
Micro-electrophoresis with a Zetasizer Nano ZS (Malvern). 1 mL of nanogels suspension 
was measured in disposable folded capillary zeta cells (Malvern, DTS1070). Z-potential is 
reported as the average of six measures per sample. 
Synthesis of (S)-4-((3-methyl-1-(nonylamino)-1-oxobutan-2-yl)amino)-4-oxobutanoic 
acid (1) and nanogel preparation 
The preparation of 1 and a detailed study of nanogel formation have been reported 
previously.9 
Rose Bengal@1 (RB@1) preparation 
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In a typical example, 7.3 µmol of compound 1 and 1 mL of a 40 M RB suspension in toluene 
(well dispersed by sonication and prepared from a 500 µM stock of RB) were introduced in 
a screw-capped vial (4 mL, diameter = 1.3 cm). A pink toluene gel with RB homogeneously 
dispersed was obtained after heating (heat gun, 250 oC) until complete solution and cooling 
down to room temperature in a water bath. The solvent from the gel was evaporated in a 
vacuum oven at 75 oC for 1 h. Then the xerogel was hydrated in 2 mL of PBS for 10 min. 
The suspension was ultrasonicated for 10 min and large particles were removed by 
centrifugation at 6000 rpm for 60 min to yield RB@1 sample as the supernatant. The amount 
of RB in the sample was quantified by measuring the absorbance of RB and comparing the 
intensity at the λmax with a calibration curve at 549 nm of RB solutions in PBS constructed 
for the range of concentration of interest. The procedure could be scaled up to prepare 
samples of RB@1 of 7 mL with a similar concentration of RB@1. For control experiments, 
RB solutions in PBS were used in the same range of concentrations of that calculated for RB 
in the RB@1 samples. 
Hypericin@1 preparation 
In a typical example, 7.3 µmol of compound 1 and 1 mL of 50 M HYP suspension in toluene 
(well dispersed by sonication) were introduced in a screw-capped vial (4 mL, diameter = 1.3 
cm). Then, the same protocol used for the preparation of RB@1 was followed. The amount 
of HYP in the samples was quantified by measuring the absorbance of HYP and comparing 
the intensity at the λmax with a calibration curve at 599 nm of HYP solutions in DMSO built 
for the range of concentrations of interest. The procedure could be scaled up to prepare 
samples of HYP@1 of 7 mL with a similar concentration of HYP@1. For control 
experiments, HYP solutions at the same concentration than in HYP@1 samples were 
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prepared in PBS containing a 1 % v/v DMSO (HYP in PBS-DMSO). HYP in PBS controls 
were prepared following HYP@1 protocol without 1.  
Measurement of 1O2 photogeneration  
Samples with a total volume of 2 mL were placed in a 10 x 10 mm fluorescence quartz cuvette 
containing ABDA 1 M as a 1O2 probe (9,10-anthracenediyl-bis (methylene)dimalonic 
acid).), (from a 0.625 mM solution in methanol). Oxygen was bubbled through the solution, 
and the cuvette was closed with a stopper and Parafilm. The sample was then irradiated, 
under continuous stirring, with visible light using a LED light for the RB study (8.6 W, ca. 
400-700 nm emission output, the lamp placed as closest to the cuvette as possible) and two 
LED lamps for the HYP study (11 W each one, ca. 400-700 nm emission output, the lamps 
placed perpendicular to each other at 1 cm from the cuvette). The cuvette was protected from 
external light during the process. The evolution of the photoreaction was monitored over time 
by fluorescence spectroscopy (λex 380 nm), following the decrease of ABDA emission 
intensity at 407 nm. The initial points of the kinetic traces were fitted to a pseudo-first-order 
model (ln C/C0 = - kobs x t, where C is the concentration of ABDA at a specific time t and C0 
is the initial concentration of ABDA). 
General considerations of biological assays 
Human colon adenocarcinoma (HT-29) cell line was obtained from the American Type 
Culture Collection (ATCC). Cell culture media were purchased from Gibco (Thermo Fisher 
Scientific). Fetal bovine serum (FBS) was obtained from Harlan-Seralab. Supplements and 
other chemicals not listed in this section were obtained from Sigma-Aldrich. Plastics for cell 
culture were supplied by Thermo Fisher Scientific. Chambered coverslips from Ibidi were 
used for confocal microscopy.  
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HT-29 cell line was maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
containing glucose (4.5 g/L), glutamine (2 mM), penicillin (50 µg/mL), streptomycin (50 
µg/mL) and amphotericin B (1.25 µg/mL), supplemented with 10% FBS. Phenol red- or 
FBS-free medium with the same supplements were used when indicated to avoid 
fluorescence interferences or to promote starving conditions, respectively. Cells were grown 
at 37 oC in a 5% CO2 humid atmosphere and, otherwise indicated, were also kept in these 
conditions during incubation. Sterilized PBS was used to wash or irradiate cells. Samples 
were tested in HT-29 cells in a 1:3 dilution with medium according to the results of the 
viability of the cells (using the Trypan blue staining method) after 24 h incubation with 
nanogels of 1 at different dilutions. 
Flow cytometry analysis was performed with a BD AccuriTM C6 flow cytometer. The data 
were recorded for at least 30,000 events per sample. When fluorescent probes were used, 
positive and negative populations were set up using an untreated or negative control cell 
population.  
Confocal laser scanning microscopy (CLSM) analysis was performed on an inverted 
confocal microscope Leica TCS SP8. Images were obtained with an HC PL APO CS2 
63x/1.40 oil immersion objective. Excitation of samples was performed with a diode laser 
excitation and fluorescence was acquired with a HyD detector, also recording the 
transmission.  
Flow cytometry evaluation of the cellular uptake of loaded nanogels 
HT-29 cells in a 6-/12-wells plate (60-70% confluence) were incubated for 24 h with the 
solutions to be tested (two replicas) in a 1:3 dilution with FBS-free and phenol red-free 
medium. After incubation, cells were harvested from the culture plates, washed three times 
with PBS, discarding the supernatant each time, and analyzed by flow cytometry. The 
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internalized probe was excited at 488 nm and the fluorescence emission per cell was 
measured using a 670LP filter for both RB and HYP. To be able to compare the data obtained 
between different experiments, results were normalized as the percentage of fluorescence 
intensity/cell over the negative control. Errors were obtained from the standard deviation of 
the duplicates and their transformation using partial derivatives based on the propagation of 
uncertainty. 
Confocal microscopy evaluation of the cellular uptake of loaded nanogels 
HT-29 cells in an µ-slide 8-wells Ibidi plate (60-70% confluence) were incubated overnight 
with the solutions to be tested in a 1:3 dilution with FBS-, phenol red-free medium. After 
washing four times with PBS, cells were kept in FBS-, phenol red-free medium, and 
visualized under the confocal microscope (RB: λex = 514 nm, HYP: λex 561 nm). The 
quantification of the fluorescence intensity of the cells was performed using ImageJ software, 
and results are expressed as the average fluorescence intensity/cell.  
PDT assays 
HT-29 cells in a 6-/12-wells plate (60-70% confluence) were incubated for 24 h with the 
solutions to be tested (two replicas) in a 1:3 dilution with phenol red-free medium. After 
incubation, cells were washed three times with PBS and, while kept in PBS, were irradiated 
for 2 min with two LED lamps (11 W each one, ca. 400-700 nm emission output) placed as 
close to the lid of the cells plate as possible resulting in an irradiance value of 750 Wm-2. In 
non-irradiated controls, the plate was kept covered in aluminum foil under the same 
conditions. After another 24 h incubation in fresh phenol red-free medium, cells were washed 
with PBS and harvested. Afterward, cells were stained and analyzed by flow cytometry 
according to the instructions of the corresponding apoptosis detection kit:the FITC Annexin 
V apoptosis detection kit I (BD Pharmingen™, 556547) for RB and the YO-PRO®-
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1/Propidium Iodide Vybrant™ Apoptosis Assay Kit #4 (V13243 Invitrogen ThermoFisher) 
for HYP. Cells populations were classified into viable (FITC Annexin V/YO-PRO®-1 and 
PI negative), apoptotic (FITC Annexin V/YO-PRO®-1 positive and PI negative), and non-
viable cells (PI-positive).70  
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